Cerulean Pharma Inc. Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced that preclinical data on CRLX101, the Company's lead nanoparticle-drug conjugate (NDC), will be reported at the American Association for Cancer Research (AACR) Annual Meeting being held in Philadelphia, PA, April 18-22. CRLX101 is a dual inhibitor of HIF-1a and topoisomerase-1 currently in clinical studies for multiple cancer types.

Help employers find you! Check out all the jobs and post your resume.